Form 4: Senti Biosciences Director Feng Hsiung Acquires Stock Options

Director Feng Hsiung of Senti Biosciences acquired stock options for 43,900 shares of common stock on March 7, 2025.

Summary

• On March 7, 2025, Feng Hsiung, a director of Senti Biosciences, Inc. (SNTI), acquired stock options.
• The options grant the right to buy 43,900 shares of Senti Biosciences common stock at an exercise price of $3.52 per share.
• The options vest in 36 equal monthly installments over three years, starting from March 7, 2025, contingent upon continued service.
• The expiration date for these options is March 6, 2035.
• Following the transaction, Hsiung directly owns 43,900 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. Option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech industry.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across the biotechnology industry.
• The vesting schedule of 36 months is fairly standard.
• The exercise price is likely determined based on the market price of SNTI stock at the time of the grant.
• Comparable companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates